Medical algorithms: Management of chronic rhinosinusitis

Fokkens, Wytske J.; Reitsma, Sietze

doi:10.1111/all.13797

Cited by 13 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If patients display mild clinical manifestations that allow home isolation, telemedical follow‐up by the physician in charge should take place to ensure proper management, and background controller treatment (topical steroids or other controller medications as recommended by current guidelines) should be continued, as described for asthma, AD, CRSwNP, and CSU 22,23,40–44 . Surgical interventions for CRSwNP should be delayed in any case possible.…”

Section: Practical and Clinical Recommendationsmentioning

confidence: 99%

Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement

Vultaggio

Agache

Akdiş³

et al. 2020

Allergy

130

View full text Add to dashboard Cite

The outbreak of the SARS‐CoV‐2‐induced coronavirus disease 2019 (COVID‐19) pandemic re‐shaped doctor‐patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS‐CoV‐2 is not known. Severe COVID‐19 patients may experience a “cytokine storm” and associated organ damage characterized by an exaggerated release of pro‐inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti‐inflammatory cytokines and type 2 responses. This expert‐based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID‐19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self‐application. In case of an active SARS‐CoV‐2 infection, biological treatment needs to be stopped until clinical recovery and SARS‐CoV‐2 negativity is established and treatment with biologicals should be re‐initiated. Maintenance of add‐on therapy and a constant assessment of disease control, apart from acute management, are demanded.

show abstract

Section: Practical and Clinical Recommendationsmentioning

confidence: 99%

Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement

Vultaggio

Agache

Akdiş³

et al. 2020

Allergy

130

View full text Add to dashboard Cite

show abstract

“…The other factors were not helpful, particularly in the postoperative period, where there does not seem to be an additive effect of macrolides over nasal corticosteroids alone (7,8) . Recently it was proposed to systematically use eosinophils (as a marker of Th2 disease) on top of phenotyping based on the presence of nasal polyps, to differentiate treatments in CRS (9) . In EPOS2012, we decided to present long-term macrolides as an option although the evidence was thin.…”

Section: Long-term Antibiotics For Chronic Rhinosinusitis: Changing Vmentioning

confidence: 99%

Long-term antibiotics for Chronic Rhinosinusitis: changing views

Wj¹

2019

Rhin

View full text Add to dashboard Cite

“…28,29 Typical treatable traits in the upper airways can be smoking, allergy, occupation, and mucociliary clearance deficits. 30 Biological therapies have entered the market for patients with asthma almost 15 years ago with anti-IgE as first-line therapy for patients with severe allergic asthma 31 and urticaria. [32][33][34][35] Recently, other monoclonal antibodies targeting type 2 inflammation 36 have been approved and are available now for patients with eosinophilic asthma, 37-41 atopic dermatitis, 42,43 and urticaria.…”

Section: Introductionmentioning

confidence: 99%

EUFOREA consensus on biologics for CRSwNP with or without asthma

Fokkens

Lund

Bachert

et al. 2019

Allergy

Self Cite

291

288

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. AbstractNovel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of | 2313 FOKKENS Et al.

show abstract

Medical algorithms: Management of chronic rhinosinusitis

Cited by 13 publications

References 11 publications

Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement

Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement

Long-term antibiotics for Chronic Rhinosinusitis: changing views

EUFOREA consensus on biologics for CRSwNP with or without asthma

Contact Info

Product

Resources

About